RESUMEN
The prospect of graft loss is a problem faced by all transplant recipients, and retransplantation is often an option when loss occurs. To assess current trends in retransplantation, we analyzed data for retransplant candidates and recipients over the last 10 years, as well as current outcomes. During 2005, retransplant candidates represented 13.5%, 7.9%, 4.1% and 5.5% of all newly registered kidney, liver, heart and lung candidates, respectively. At the end of 2005, candidates for retransplantation accounted for 15.3% of kidney transplant candidates, and lower proportions of liver (5.1%), heart (5.3%) and lung (3.3%) candidates. Retransplants represented 12.4% of kidney, 9.0% of liver, 4.7% of heart and 5.3% of lung transplants performed in 2005. The absolute number of retransplants has grown most notably in kidney transplantation, increasing 40% over the last 10 years; the relative growth of retransplantation was most marked in heart and lung transplantation, increasing 66% and 217%, respectively. The growth of liver retransplantation was only 11%. Unadjusted graft survival remains significantly lower after retransplantation in the most recent cohorts analyzed. Even with careful case mix adjustments, the risk of graft failure following retransplantation is significantly higher than that observed for primary transplants.
Asunto(s)
Trasplante de Órganos/estadística & datos numéricos , Reoperación/estadística & datos numéricos , Supervivencia de Injerto , Trasplante de Corazón/estadística & datos numéricos , Humanos , Trasplante de Riñón/estadística & datos numéricos , Trasplante de Hígado/estadística & datos numéricos , Trasplante de Pulmón/estadística & datos numéricos , Trasplante de Órganos/tendencias , Reoperación/tendencias , Insuficiencia del Tratamiento , Resultado del Tratamiento , Estados Unidos , Listas de EsperaRESUMEN
UNLABELLED: Islet transplantation offers a potential cure for type I diabetes, although its success has been limited, due to loss of cells by apoptosis stimulated by the procurement, ischemia, and the isolation process itself. RNA interference (RNAi) as mediated by short interfering RNAs (siRNAs) has become a potent tool to manipulate gene expression in mammalian cells. We describe the first successful introduction of siRNA directly into pancreatic islet cells both during in situ perfusion and from intravenous tail vein injection (in vivo). METHODS: siRNA was targeted to the pancreatic islets of BALB/c mice by retrograde portal vein perfusion or tail vein injection. Cy3-labeled siRNA was dissolved in University of Wisconsin (UW) solution at 2 microg/mL. After delivery pancreata were placed in cold storage at 4 degrees C in UW solution for 24 hours, followed by processing for immunofluorescent staining for insulin. Fluorescent imaging was obtained using a Nikon DIAPHOT 300 Inverted Micoscope with a Zeiss AxioCam and OpenLab image capturing software. RESULTS: In situ delivery of siRNA was demonstrated by fluorescent imaging composites of (red) siRNA in and along (green) insulin stained islets from pancreas sections as compared with untreated control sections. The siRNA was detected mainly in and along venous structures throughout the pancreatic tissue. In vivo delivery of siRNA into islets was observed by fluorescent images taken of isolated islets in culture. CONCLUSIONS: We have described the successful delivery of siRNA to pancreatic islets via a novel in situ pancreas perfusion technique and in vivo delivery via tail vein injection.
Asunto(s)
Trasplante de Islotes Pancreáticos/fisiología , Islotes Pancreáticos/fisiología , ARN Interferente Pequeño/metabolismo , Adenosina , Alopurinol , Animales , Secuencia de Bases , Glutatión , Inyecciones Intravenosas , Insulina/metabolismo , Secreción de Insulina , Islotes Pancreáticos/citología , Ratones , Ratones Endogámicos BALB C , Microscopía Fluorescente , Soluciones Preservantes de Órganos , ARN Interferente Pequeño/administración & dosificación , RafinosaRESUMEN
The incidence, timing and site of infections among the different categories of pancreas transplant recipients were investigated. Patients were divided into three groups: pancreas transplant alone (PTA), pancreas after kidney transplant (PAK), or simultaneous pancreas and kidney (SPK) transplants. Length of follow-up, time to death, pancreas graft survival, incidence, timing and site of bacterial infections were noted. Our study showed that at least 75% of pancreas transplant recipients experienced at least one infection (range from 77.8% in the PTA group to 86.7% in the PAK group). The SPK group presented the highest rate of infections with 35.1 infections per 1000/patient-days. Symptomatic urinary tract infections were the most common cause of infection in all patients. The incidence of infections was higher during the first month after transplantation, except for the SPK transplant group, where infections occurred over a longer time period.
Asunto(s)
Infecciones Bacterianas/epidemiología , Trasplante de Páncreas/efectos adversos , Adulto , Infecciones Bacterianas/etiología , Femenino , Humanos , Incidencia , Trasplante de Riñón/efectos adversos , Masculino , Persona de Mediana Edad , Factores de TiempoRESUMEN
Aspergillus osteomyelitis is a rare complication of invasive aspergillosis after organ transplantation. This is the report of a 46-year-old man who underwent a simultaneous pancreas and kidney transplantation, complicated by an Aspergillus osteomyelitis and diskitis of the lumbar spine. Prompt diagnosis with needle biopsy, followed by antifungal therapy using caspofungin, a new antifungal agent recommended for the treatment of refractory aspergillosis, in combination with amphotericin B and an early surgical intervention led to clinical resolution of the infection. Reported cases of spinal aspergillosis after transplantation are reviewed in terms of clinical presentation, risk factors, therapeutic options, and outcome.
Asunto(s)
Aspergilosis/etiología , Trasplante de Riñón/efectos adversos , Osteomielitis/etiología , Trasplante de Páncreas/efectos adversos , Enfermedades de la Columna Vertebral/etiología , Aspergilosis/tratamiento farmacológico , Humanos , Masculino , Persona de Mediana EdadRESUMEN
BACKGROUND: Osteoporosis is a serious complication of kidney transplantation. Various factors have been postulated to contribute to posttransplant bone loss, among them treatment with corticosteroids, the use of cyclosporine and cyclosporine-like agents, and persistent hyperparathyroidism. In a previous cross-sectional study of long-term renal transplant recipients, we observed that osteoporosis or osteopenia was present in 88% of patients. Because biochemical markers of bone formation (serum osteocalcin) and bone resorption (urine pyridinoline, PYD, and deoxypyridinoline, DPD) were elevated in the majority of study subjects, we hypothesized that elevated rates of bone-turnover contribute to posttransplant bone loss in long-term renal transplant patients. This study was performed to examine this hypothesis. METHODS: The study population was composed of 62 patients who were more than 1-year postrenal transplantation and who had preserved renal function. They were followed prospectively for 1 year. Biochemical markers of bone-turnover were measured at study entry, and patients were classified as having high bone-turnover based on elevated urinary levels of at least one marker of bone resorption (i.e., PYD or DPD) and/or serum osteocalcin (group 1). If none of these were present, they were classified as having normal bone-turnover (group 2). Bone mineral density (BMD) was measured by dual energy x-ray absorptiometry (DEXA) at time of entry into the study and again after 1 year of follow-up. The changes in BMD at the lumbar spine, hip, and wrist over the period of the study were compared between the high and normal bone-turnover groups. RESULTS: Forty-three patients (69%) were classified as having high bone-turnover (Group 1), and 19 patients (31%) were classified as having normal bone-turnover (Group 2). There was a statistically significant difference in change in BMD between the two groups at the lumbar spine (-1.11+/-0.42%, high bone-turnover, vs. 0.64+/-0.54%, normal bone-turnover; P=0.02) and the hip (-0.69+/-0.38%, high bone-turnover, vs. 1.36+/-0.66%, normal bone-turnover; P=0.006). Whereas group 2 had stable bone mass, group 1 exhibited bone loss at these skeletal sites. CONCLUSIONS: Our results indicate that bone loss is greater in renal transplant recipients with elevated biochemical markers of bone-turnover, suggesting that these markers may be useful in identifying patients at risk for continued bone loss. These data support the hypothesis that continued bone loss in long-term renal transplant recipients is associated with high bone-turnover. If accelerated bone resorption does play a role in posttransplant bone loss, this would provide a strong rationale for use of antiresorptive therapy for the prevention and treatment of this complication.
Asunto(s)
Remodelación Ósea , Trasplante de Riñón/efectos adversos , Osteoporosis/etiología , Aminoácidos/orina , Biomarcadores , Densidad Ósea , Femenino , Humanos , Estudios Longitudinales , Masculino , Persona de Mediana Edad , Osteocalcina , Hormona Paratiroidea/sangre , Pronóstico , Estudios ProspectivosRESUMEN
This paper describes the organization of infection control in Italy with respect to regulatory requirements, the tasks and training of the infection control physician and nurse, and the function and responsibilities of the infection control committee. Moreover, the paper reports on incidence and prevalence of hospital-acquired infections (HAI), antibiotic usage and antimicrobial resistance in Italy.
Asunto(s)
Control de Infecciones/organización & administración , Antibacterianos/uso terapéutico , Farmacorresistencia Microbiana , Regulación y Control de Instalaciones , Humanos , Profesionales para Control de Infecciones/educación , Italia , Personal de Enfermería/educación , Ejecutivos Médicos/educación , Comité de ProfesionalesRESUMEN
Cytolytic T lymphocyte-associated antigen 4 (CTLA-4) is a critical down-regulatory molecule in T cells that plays a major role in peripheral tolerance. Although the CD45 protein tyrosine phosphatase is a potent immunomodulatory target, the mechanisms by which antibody against CD45RB isoforms (anti-CD45RB) induces allograft tolerance remain unclear. We show here that anti-CD45RB treatment alters CD45 isoform expression on T cells, which is associated with rapid up-regulation of CTLA-4 expression. These effects appear specific and occur without up-regulation of other activation markers. Administration of a blocking monoclonal antibody to CTLA-4 at the time of transplantation prevents anti-CD45RB therapy from prolonging islet allograft survival. In addition, treatment with cyclosporin A blocks anti-CD45RB-induced CTLA-4 expression and promotes acute rejection. These data suggest that anti-CD45RB acts through mechanisms that include CTLA-4 up-regulation and demonstrate a link between CD45 and CTLA-4 that depends on calcineurin-mediated signaling. They demonstrate also that CTLA-4 expression may be specifically targeted to enhance allograft acceptance.
Asunto(s)
Antígenos de Diferenciación/biosíntesis , Tolerancia Inmunológica , Inmunoconjugados , Antígenos Comunes de Leucocito/metabolismo , Abatacept , Animales , Antígenos CD , Antígeno CTLA-4 , Calcineurina/metabolismo , Supervivencia de Injerto/inmunología , Trasplante de Islotes Pancreáticos/inmunología , Activación de Linfocitos , Masculino , Ratones , Ratones Endogámicos BALB C , Ratones Endogámicos C57BL , Transducción de Señal , Linfocitos T/inmunología , Linfocitos T/metabolismo , Trasplante Homólogo , Regulación hacia ArribaAsunto(s)
Anticuerpos Monoclonales/uso terapéutico , Ligando de CD40/inmunología , Supervivencia de Injerto/inmunología , Trasplante de Islotes Pancreáticos/inmunología , Antígenos Comunes de Leucocito/inmunología , Animales , Trasplante de Islotes Pancreáticos/fisiología , Ratones , Ratones Endogámicos C57BL , Ratones Endogámicos NOD , Factores de Tiempo , Trasplante HomólogoRESUMEN
The induction and maintenance of allograft tolerance is a daunting challenge. Although combined blockade of CD28 and CD40 ligand (CD40L)-costimulatory pathways prevents allograft rejection in some murine models, this strategy is unable to sustain engraftment in the most immunogenic allograft and strain combinations. By targeting T cell activation signals 1 and 2 with the novel combination of anti-CD45RB and anti-CD40L, we now demonstrate potent enhancement of engraftment in C57BL/6 recipients that are relatively resistant to costimulatory blockade. This combination significantly augments the induction of tolerance to islet allografts and dramatically prolongs primary skin allograft survival. Compared with either agent alone, anti-CD45RB plus anti-CD40L inhibits periislet infiltration by CD8 cells, B cells, and monocytes; inhibits Th1 cytokines; and increases Th2 cytokine expression within the graft. These data indicate that interference with activation signals one and two may provide synergy essential for prolonged engraftment in situations where costimulatory blockade is only partially effective.
Asunto(s)
Anticuerpos Bloqueadores/uso terapéutico , Anticuerpos Monoclonales/uso terapéutico , Ligando de CD40/inmunología , Supervivencia de Injerto/inmunología , Antígenos Comunes de Leucocito/inmunología , Transducción de Señal/inmunología , Tolerancia al Trasplante , Adyuvantes Inmunológicos/uso terapéutico , Animales , Linfocitos B/patología , Linfocitos T CD8-positivos/patología , Movimiento Celular/inmunología , Citocinas/biosíntesis , Quimioterapia Combinada , Trasplante de Islotes Pancreáticos/inmunología , Trasplante de Islotes Pancreáticos/patología , Antígenos Comunes de Leucocito/biosíntesis , Antígenos Comunes de Leucocito/fisiología , Masculino , Ratones , Ratones Endogámicos BALB C , Ratones Endogámicos C57BL , Modelos Inmunológicos , Monocitos/patología , Isoformas de Proteínas/biosíntesis , Trasplante de Piel/inmunologíaRESUMEN
Loss of bone is a significant problem after renal transplant. Although bone loss in the first post transplant year has been well documented, conflicting data exist concerning bone loss after this time. It is equally unclear whether bone loss in long-term renal transplant recipients correlates with bone turnover as it does in postmenapausal osteoporosis. To examine these issues, we conducted a cross-sectional study to define the prevalence of osteoporosis in long-term (> 1 year) renal transplant recipients with preserved renal function (mean creatinine clearance 73 +/- 23 ml/min). Bone mineral density (BMD) was measured at the hip, spine and wrist by DEXA in 69 patients. Markers for bone formation (serum osteocalcin) and bone resorption [urinary levels of pyridinoline (PYD) and deoxypyridinoline (DPD)] were also measured as well as parameters of calcium metabolism. Correlations were made between these parameters and BMD at the various sites. The mean age of the patients was 45 +/- 11 years. Eighty eight percent of patients were on cyclosporine (12% on tacrolimus) and all but 2 were on prednisone [mean dose 9 +/- 2 mg/day)]. Osteoporosis (BMD more than 2.5 SD below peak adult BMD) at the spine or hip was diagnosed in 44% of patients and osteopenia was present in an additional 44%. Elevated levels of intact parathyroid hormone (i PTH) were observed in 81% of patients. Elevated urinary levels of PYD or DPD were present in 73% of patients and 38% had elevated serum levels of osteocalcin. Levels of calcium, and of 25(OH) and 1,25(OH)2 vitamin D were normal. In a stepwise multiple regression model that included osteocalcin, PYD, DPD, intact PTH, age, years posttransplant, duration of dialysis, cumulative prednisone dose, smoking, and diabetes: urinary PYD was the strongest predictor of bone mass. These results demonstrate that osteoporosis is common in long-term renal transplant recipients. The data also suggest that elevated rates of bone resorption contribute importantly to this process.
Asunto(s)
Resorción Ósea/etiología , Trasplante de Riñón/efectos adversos , Osteoporosis/etiología , Adulto , Anciano , Aminoácidos/orina , Densidad Ósea , Enfermedades Óseas Metabólicas/etiología , Calcio/metabolismo , Estudios Transversales , Femenino , Humanos , Trasplante de Riñón/fisiología , Masculino , Persona de Mediana Edad , Osteocalcina/sangre , Prednisona/administración & dosificación , Prednisona/efectos adversosRESUMEN
BACKGROUND: Thymoglobulin, a rabbit anti-human thymocyte globulin, was compared with Atgam, a horse anti-human thymocyte globulin for the treatment of acute rejection after renal transplantation. METHODS: A multicenter, double-blind, randomized trial with enrollment stratification based on standardized histology (Banff grading) was conducted. Subjects received 7-14 days of Thymoglobulin (1.5 mg/kg/ day) or Atgam (15 mg/kg/day). The primary end point was rejection reversal (return of serum creatinine level to or below the day 0 baseline value). RESULTS: A total of 163 patients were enrolled at 25 transplant centers in the United States. No differences in demographics or transplant characteristics were noted. Intent-to-treat analysis demonstrated that Thymoglobulin had a higher rejection reversal rate than Atgam (88% versus 76%, P=0.027, primary end point). Day 30 graft survival rates (Thymoglobulin 94% and Atgam 90%, P=0.17), day 30 serum creatinine levels as a percentage of baseline (Thymoglobulin 72% and Atgam 80%; P=0.43), and improvement in posttreatment biopsy results (Thymoglobulin 65% and Atgam 50%; P=0.15) were not statistically different. T-cell depletion was maintained more effectively with Thymoglobulin than Atgam both at the end of therapy (P=0.001) and at day 30 (P=0.016). Recurrent rejection, at 90 days after therapy, occurred less frequently with Thymoglobulin (17%) versus Atgam (36%) (P=0.011). A similar incidence of adverse events, post-therapy infections, and 1-year patient and graft survival rates were observed with both treatments. CONCLUSIONS: Thymoglobulin was found to be superior to Atgam in reversing acute rejection and preventing recurrent rejection after therapy in renal transplant recipients.
Asunto(s)
Suero Antilinfocítico/uso terapéutico , Rechazo de Injerto/terapia , Inmunosupresores/uso terapéutico , Trasplante de Riñón , Enfermedad Aguda , Adolescente , Adulto , Anciano , Animales , Suero Antilinfocítico/efectos adversos , Método Doble Ciego , Femenino , Humanos , Masculino , Persona de Mediana Edad , ConejosRESUMEN
CD45 is a family of transmembrane protein tyrosine phosphatases exclusively expressed by hematopoietic cells and critically involved in the regulation of T cell activation signals. We now demonstrate that three 100-microg doses of anti-CD45RB mAb MB23G2 can induce long-term engraftment of islets into major histcompatibility complex-disparate chemically diabetic mice. Long-term graft survivors (>120 days) were tolerant to new islet allografts from the original donor strain. MB23G2 induced a temporary decrease in number circulating leukocytes but had no effect on leukocyte number in other lymphoid compartments. Histologic examination of allografts from treated and untreated recipients revealed a similar peri-islet infiltration on day 6. Eleven days after transplant, the peri-islet infiltrate in treated animals persisted, but in marked contrast to untreated control animals, there was no insulitis and islet integrity was preserved. The peri-islet infiltrate from treated animals showed a mild increase in CD4 cells, a decrease in CD8 cells, and decreased intensity of CD45RB expression. Treatment of naive animals with anti-CD45RB (MB23G2) resulted in a shift in CD45 isoform expression on T cells with a loss of higher molecular weight isoforms and increased expression of lower molecular weight (CD45R0) isoform. This shift in CD45 isoform expression from CD45RBHi to CD45RBLo was associated with an increase in the intragraft expression of transcripts for interleukin (IL) 4 and IL-10, consistent with the expected activity of this distinct immunoregulatory T cell subset. Antibody-mediated targeting of CD45 may induce tolerance through novel mechanisms and have direct applicability to clinical transplantation in humans.
Asunto(s)
Anticuerpos/uso terapéutico , Diabetes Mellitus Experimental/cirugía , Rechazo de Injerto/prevención & control , Inmunoterapia , Trasplante de Islotes Pancreáticos/inmunología , Antígenos Comunes de Leucocito/inmunología , Inmunología del Trasplante , Animales , Anticuerpos/inmunología , Tolerancia Inmunológica , Masculino , Ratones , Ratones Endogámicos BALB C , Ratones Endogámicos C57BL , Trasplante HomólogoRESUMEN
BACKGROUND: Posttransplant lymphoproliferative disorder (PTLD) has been observed with increasing frequency consequent to the availability of more effective and potent immunosuppression. Prior work suggested that a peripheral blood monitoring strategy detecting peripheral B lymphoproliferation was effective in the early diagnosis of PTLD among 7 of 179 (3.9%) consecutive transplant recipients. Each of those seven patients received at least one course of antithymocyte globulin, Minnesota antilymphocyte globulin, or OKT3 before developing PTLD. METHODS: To determine whether antiviral prophylaxis might reduce the incidence of PTLD, a subsequent group of 198 consecutive recipients received either ganciclovir or acyclovir during antilymphocyte antibody administration. When the donor or recipient were cytomegalovirus-seropositive, ganciclovir was given; acyclovir was used when both were cytomegalovirus-seronegative. Baseline and protocol posttransplant cell surface profiles were obtained using immunofluorescence and flow cytometry to detect T cells, lymphocyte activation markers, and the CD19 B cell antigen. RESULTS: Demographic factors, including the incidence of recipients more than 50 years of age, non-Caucasians, previous transplantation, and diabetes mellitus, were similar in both groups. Additionally, the number of patients receiving antilymphocyte preparations was similar. However, only one patient (0.5%) from the latter group who received preemptive antiviral therapy developed PTLD. Although elevations in CD19+ B cells preceded clinical PTLD among each of the seven earlier patients, evidence of peripheral B cell proliferation was not demonstrated for the sole patient from the latter group, which suggests a possible effect of antiviral therapy. CONCLUSIONS: Prophylactic antiviral therapy may reduce the sensitivity of peripheral monitoring for B lymphoproliferation, but the dramatic reduction in PTLD incidence strongly supports its use among transplant recipients at risk.
Asunto(s)
Aciclovir/uso terapéutico , Antivirales/uso terapéutico , Ganciclovir/uso terapéutico , Herpesvirus Humano 4 , Trastornos Linfoproliferativos/epidemiología , Complicaciones Posoperatorias/prevención & control , Adolescente , Adulto , Antígenos CD/análisis , Antígenos CD19/análisis , Suero Antilinfocítico/uso terapéutico , Humanos , Inmunofenotipificación , Inmunosupresores/uso terapéutico , Incidencia , Trasplante de Riñón , Trasplante de Hígado , Trastornos Linfoproliferativos/prevención & control , Trastornos Linfoproliferativos/virología , Persona de Mediana Edad , Muromonab-CD3/uso terapéutico , Trasplante de Páncreas , Estudios RetrospectivosRESUMEN
BACKGROUND: Although islet cell transplantation is considered an ideal form of endocrine replacement for type I diabetes, clinical application in humans is still not feasible. New immunosuppressive strategies are clearly needed to control inexorable rejection. CD45 is a family of transmembrane protein tyrosine phosphatases critically involved in the regulation of lymphocyte activation signals. Anti-CD45RB monoclonal antibody can prevent rejection of murine renal allografts. METHODS: Here, we examine the consequences of targeting CD45 in murine islet cell transplantation. Diabetic mice recipients received islet allografts under the kidney capsule and were divided into seven groups. Recipients received no treatment (controls) or anti-CD45RB monoclonal antibody (mAb; MB23G2 or C363.16A) at different dosages and treatment intervals. RESULTS: All untreated control animals lost islet function, becoming hyperglycemic within 10-17 days after transplantation. Animals treated with either anti-CD45RB mAb showed a significant prolongation of islet allograft survival when compared with controls. Anti-CD45RB MB23G2 at 100 microg/day, given on days -1, 0, and 5 was particularly effective, inducing indefinite islet allograft survival in 60% of recipients. CONCLUSIONS: These results indicate that anti-CD45 mAbs are potent immunomodulatory agents, able to sustain indefinite islet allograft function after a short treatment course in the highly immunogenic model of islet transplantation.
Asunto(s)
Anticuerpos Monoclonales/farmacología , Supervivencia de Injerto/efectos de los fármacos , Inmunosupresores/farmacología , Trasplante de Islotes Pancreáticos/inmunología , Antígenos Comunes de Leucocito/inmunología , Animales , Masculino , Ratones , Ratones Endogámicos BALB C , Ratones Endogámicos C57BL , Trasplante HomólogoAsunto(s)
Anticuerpos Monoclonales/uso terapéutico , Diabetes Mellitus Experimental/terapia , Supervivencia de Injerto/inmunología , Terapia de Inmunosupresión/métodos , Trasplante de Islotes Pancreáticos/inmunología , Antígenos Comunes de Leucocito/inmunología , Animales , Glucemia/metabolismo , Exones , Trasplante de Islotes Pancreáticos/fisiología , Antígenos Comunes de Leucocito/genética , Ratones , Ratones Endogámicos BALB C , Ratones Endogámicos C57BL , Trasplante Homólogo , Trasplante IsogénicoAsunto(s)
Arteriolas/patología , Conjuntiva/irrigación sanguínea , Diabetes Mellitus Tipo 1/cirugía , Retinopatía Diabética/fisiopatología , Trasplante de Riñón/fisiología , Trasplante de Páncreas/fisiología , Vénulas/patología , Diabetes Mellitus Tipo 1/fisiopatología , Nefropatías Diabéticas/cirugía , Retinopatía Diabética/patología , Estudios de Seguimiento , Humanos , Fallo Renal Crónico/cirugía , MicrocirculaciónAsunto(s)
Prueba de Histocompatibilidad , Trasplante de Riñón/inmunología , Trasplante de Páncreas/inmunología , Ciclosporina/uso terapéutico , Rechazo de Injerto/epidemiología , Rechazo de Injerto/terapia , Humanos , Inmunosupresores/uso terapéutico , Trasplante de Riñón/fisiología , Muromonab-CD3/uso terapéutico , Trasplante de Páncreas/fisiología , Estudios Retrospectivos , Tacrolimus/uso terapéutico , Donantes de Tejidos , Resultado del TratamientoAsunto(s)
Constitución Corporal , Rechazo de Injerto/epidemiología , Supervivencia de Injerto , Trasplante de Riñón , Riñón/anatomía & histología , Donantes de Tejidos , Obtención de Tejidos y Órganos/organización & administración , Superficie Corporal , Peso Corporal , Enfermedad Crónica , Rechazo de Injerto/etiología , Humanos , Análisis Multivariante , Análisis de Regresión , Estudios Retrospectivos , Factores de RiesgoRESUMEN
To determine whether preoperative intravenous hydration was an important determinant of perioperative safety for the kidney donor or of early allograft function, 21 consecutive living donor transplants were assessed retrospectively. Donors hospitalized overnight received 1008 +/- 169 mL of intravenous fluid during the 8 h prior to operation, compared to no preoperative hydration among a cohort of 15 patients. No differences between intraoperative blood pressures, fluid administration, urine output, or time in the operating room were identified between groups. Postoperative allograft function was not compromised by the lack of hydration. We conclude that living kidney donors can safely undergo elective nephrectomy without prior intravenous hydration.